#mrna

Researchers report a way to use engineered red blood cells to ferry mRNA into the body and reprogram myeloid immune cells to attack tumors, pointing to a potential alternative to conventional CAR cell manufacturing.

Researchers at the University of Trento report an mRNA-based genome-editing approach aimed at a cystic fibrosis mutation that affects about 10% of patients and does not respond to some current drug therapies.

Moderna and Merck are describing a personalized mRNA cancer treatment as a therapy rather than a vaccine, reflecting how politics and regulation are reshaping biotech language.

Scientists have developed DoriVac, a DNA nanostructure vaccine platform producing stronger and more durable immune responses than mRNA vaccines in early studies, with applications targeting HIV, Ebola, and COVID-19.

Ugur Sahin and Ozlem Tureci will exit BioNTech by year-end to start a company focused on next-generation mRNA innovations.

Moderna agrees to pay $950 million to settle long-running patent claims with Arbutus and Roivant over lipid nanoparticle technology used in its COVID vaccine.